New Delhi: Drug firm Jubilant Life Sciences has received approval from the US health regulator to market Indomethacin capsule used for treating pains.
Jubilant Life Sciences said in a filing to the BSE that it "received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (USFDA) for Indomethacin ER Capsule 75mg, which is a non-steriodal anti-inflammatory drug used for treatment of pain".
As on June 30, 2015, Jubilant Life Sciences said had a total of 815 filings for formulations of which 389 have been approved in various regions globally, it said.
"This includes 72 ANDAs filed in the US, of which 38 have been approved and 46 Dossier filings in Europe," it added.
As of 1:42 p.m., shares in Jubilant Life Sciences were trading nearly 1 per cent higher at Rs 399.35 apiece on the BSE, outperforming the broader Sensex that was up 0.2 per cent.